Ludimila L. Cavalcante

Closest collaborators

The 17 strongest of 17 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Andrew L. Coveler · 2 shared papers, 2021–2025 · strength 0.38
   • Paper Phase II study of elraglusib (9-ING-41), a GSK-3β inhibitor, in combination with gemcitabine plus nab-paclitaxel in pre… DOI 10.1016/j.esmoop.2025.105122↗
   • Paper GSK-3β in Pancreatic Cancer: Spotlight on 9-ING-41, Its Therapeutic Potential and Immune Modulatory Properties. DOI 10.3390/biology10070610↗
2. Anwaar Saeed · 2 shared papers, 2021–2025 · strength 0.38
   • Paper Phase II study of elraglusib (9-ING-41), a GSK-3β inhibitor, in combination with gemcitabine plus nab-paclitaxel in pre… DOI 10.1016/j.esmoop.2025.105122↗
   • Paper GSK-3β in Pancreatic Cancer: Spotlight on 9-ING-41, Its Therapeutic Potential and Immune Modulatory Properties. DOI 10.3390/biology10070610↗
3. Alexander Grenander Raufi · 1 shared paper, 2025 · strength 0.19
   • Paper Phase II study of elraglusib (9-ING-41), a GSK-3β inhibitor, in combination with gemcitabine plus nab-paclitaxel in pre… DOI 10.1016/j.esmoop.2025.105122↗
4. Steven Francis Powell · 1 shared paper, 2025 · strength 0.19
   • Paper Phase II study of elraglusib (9-ING-41), a GSK-3β inhibitor, in combination with gemcitabine plus nab-paclitaxel in pre… DOI 10.1016/j.esmoop.2025.105122↗
5. Benedito A. Carneiro · 1 shared paper, 2025 · strength 0.19
   • Paper Phase II study of elraglusib (9-ING-41), a GSK-3β inhibitor, in combination with gemcitabine plus nab-paclitaxel in pre… DOI 10.1016/j.esmoop.2025.105122↗
6. Marisol Huerta · 1 shared paper, 2025 · strength 0.19
   • Paper Phase II study of elraglusib (9-ING-41), a GSK-3β inhibitor, in combination with gemcitabine plus nab-paclitaxel in pre… DOI 10.1016/j.esmoop.2025.105122↗
7. Andrès M.R. Cervantes · 1 shared paper, 2025 · strength 0.19
   • Paper Phase II study of elraglusib (9-ING-41), a GSK-3β inhibitor, in combination with gemcitabine plus nab-paclitaxel in pre… DOI 10.1016/j.esmoop.2025.105122↗
8. Devalingam Mahalingam · 1 shared paper, 2025 · strength 0.19
   • Paper Phase II study of elraglusib (9-ING-41), a GSK-3β inhibitor, in combination with gemcitabine plus nab-paclitaxel in pre… DOI 10.1016/j.esmoop.2025.105122↗
9. Jordan D. Berlin · 1 shared paper, 2025 · strength 0.19
   • Paper Phase II study of elraglusib (9-ING-41), a GSK-3β inhibitor, in combination with gemcitabine plus nab-paclitaxel in pre… DOI 10.1016/j.esmoop.2025.105122↗
10. Vaibhav Sahai · 1 shared paper, 2025 · strength 0.19
    • Paper Phase II study of elraglusib (9-ING-41), a GSK-3β inhibitor, in combination with gemcitabine plus nab-paclitaxel in pre… DOI 10.1016/j.esmoop.2025.105122↗
11. Mary F. Mulcahy · 1 shared paper, 2025 · strength 0.19
    • Paper Phase II study of elraglusib (9-ING-41), a GSK-3β inhibitor, in combination with gemcitabine plus nab-paclitaxel in pre… DOI 10.1016/j.esmoop.2025.105122↗
12. Robin Park · 1 shared paper, 2021 · strength 0.19
    • Paper GSK-3β in Pancreatic Cancer: Spotlight on 9-ING-41, Its Therapeutic Potential and Immune Modulatory Properties. DOI 10.3390/biology10070610↗
13. Subhasis Misra · 1 shared paper, 2024 · strength 0.18
    • Paper Pancreatic ductal adenocarcinoma: exploring clinicopathological trends and racial disparities in a comprehensive U.S. p… DOI 10.1007/s12094-024-03484-7↗
14. Abdul Qahar Khan Yasinzai · 1 shared paper, 2024 · strength 0.18
    • Paper Pancreatic ductal adenocarcinoma: exploring clinicopathological trends and racial disparities in a comprehensive U.S. p… DOI 10.1007/s12094-024-03484-7↗
15. Asad Ullah · 1 shared paper, 2024 · strength 0.18
    • Paper Pancreatic ductal adenocarcinoma: exploring clinicopathological trends and racial disparities in a comprehensive U.S. p… DOI 10.1007/s12094-024-03484-7↗
16. David Paul Kelsen · 1 shared paper, 2014 · strength 0.07
    • Paper Combined modality therapy in pancreatic adenocarcinoma: review and updates on a controversial issue. DOI 10.2174/1381612820666140826154724↗
17. Kenneth H. Yu · 1 shared paper, 2014 · strength 0.07
    • Paper Combined modality therapy in pancreatic adenocarcinoma: review and updates on a controversial issue. DOI 10.2174/1381612820666140826154724↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.